Details for New Drug Application (NDA): 212904
✉ Email this page to a colleague
NDA 212904 describes FOTIVDA, which is a drug marketed by Aveo Pharms and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the FOTIVDA profile page.
The generic ingredient in FOTIVDA is tivozanib hydrochloride. One supplier is listed for this compound. Additional details are available on the tivozanib hydrochloride profile page.
The generic ingredient in FOTIVDA is tivozanib hydrochloride. One supplier is listed for this compound. Additional details are available on the tivozanib hydrochloride profile page.
Summary for 212904
| Tradename: | FOTIVDA |
| Applicant: | Aveo Pharms |
| Ingredient: | tivozanib hydrochloride |
| Patents: | 3 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 212904
Generic Entry Date for 212904*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 212904
| Mechanism of Action | Tyrosine Kinase Inhibitors |
Suppliers and Packaging for NDA: 212904
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904 | NDA | AVEO Pharmaceuticals, Inc. | 45629-089 | 45629-089-01 | 24 BOTTLE, PLASTIC in 1 CARTON (45629-089-01) / 21 CAPSULE in 1 BOTTLE, PLASTIC |
| FOTIVDA | tivozanib hydrochloride | CAPSULE;ORAL | 212904 | NDA | AVEO Pharmaceuticals, Inc. | 45629-134 | 45629-134-01 | 24 BOTTLE, PLASTIC in 1 CARTON (45629-134-01) / 21 CAPSULE in 1 BOTTLE, PLASTIC |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 0.89MG BASE | ||||
| Approval Date: | Mar 10, 2021 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Mar 10, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Nov 5, 2039 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Apr 26, 2025 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR | ||||||||
Complete Access Available with Subscription
